Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients.
Cutuli B, Lemanski C, De Lafontan B, Chauvet MP, De Lara CT, Mege A, Fric D, Richard-Molard M, Mazouni C, Cuvier C, Carre A, Kirova Y. Cutuli B, et al. Among authors: de lara ct. Clin Breast Cancer. 2020 Apr;20(2):e164-e172. doi: 10.1016/j.clbc.2019.08.002. Epub 2019 Aug 22. Clin Breast Cancer. 2020. PMID: 31780381 Free article.
Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations.
de Mascarel I, Bonichon F, MacGrogan G, de Lara CT, Avril A, Picot V, Durand M, Mauriac L, Trojani M, Coindre JM. de Mascarel I, et al. Among authors: de lara ct. Breast Cancer Res Treat. 2000 May;61(2):151-9. doi: 10.1023/a:1006437902770. Breast Cancer Res Treat. 2000. PMID: 10942101
Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network.
Bousquet G, Confavreux C, Magné N, de Lara CT, Poortmans P, Senkus E, de Lafontan B, Bolla M, Largillier R, Lagneau E, Kadish S, Lemanski C, Ozsahin M, Belkacémi Y. Bousquet G, et al. Among authors: de lara ct, de lafontan b. Radiother Oncol. 2007 Dec;85(3):355-61. doi: 10.1016/j.radonc.2007.10.015. Epub 2007 Nov 26. Radiother Oncol. 2007. PMID: 18023492
Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases.
Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H, de Lara CT, Edeline J, Penault-Llorca F, Romestaing P, Delva C, Comet B, Belkacemi Y. Cutuli B, et al. Among authors: de lara ct, de lafontan b. Crit Rev Oncol Hematol. 2010 Mar;73(3):246-54. doi: 10.1016/j.critrevonc.2009.04.002. Epub 2009 May 12. Crit Rev Oncol Hematol. 2010. PMID: 19442535
[Ductal carcinoma in situ of the breast (DCIS). Histopathological features and treatment modalities: analysis of 1,289 cases].
Cutuli B, Lemanski C, Fourquet A, de Lafontan B, Giard S, Lancrenon S, Meunier A, Pioud-Martigny R, Campana F, Marsiglia H, Mery E, Penault-Llorca F, Fondrinier E, de Lara CT. Cutuli B, et al. Among authors: de lara ct, de lafontan b. Bull Cancer. 2010 Mar;97(3):301-10. doi: 10.1684/bdc.2010.1048. Bull Cancer. 2010. PMID: 20159677 French.
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.
Houvenaeghel G, de Nonneville A, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo PE, Gimbergues P, Chauvet MP, Azuar AS, Rouzier R, de Lara CT, Muracciole X, Agostini A, Gonçalves A, Lambaudie E. Houvenaeghel G, et al. Among authors: de lara ct. Breast Cancer Res Treat. 2019 Jan;173(1):111-122. doi: 10.1007/s10549-018-4944-2. Epub 2018 Sep 20. Breast Cancer Res Treat. 2019. PMID: 30238274
Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, Rouzier R, Faure C, Paillocher N, Chauvet MP, Houvenaeghel G, Gutowski M, De Blay P, Verhaeghe JL, Barranger E, Lefebvre C, Ngo C, Ferron G, Palpacuer C, Campion L. Classe JM, et al. Among authors: de lara ct. Breast Cancer Res Treat. 2019 Jan;173(2):343-352. doi: 10.1007/s10549-018-5004-7. Epub 2018 Oct 20. Breast Cancer Res Treat. 2019. PMID: 30343457 Clinical Trial.
Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
Houvenaeghel G, Cohen M, Raro P, De Troyer J, de Lara CT, Gimbergues P, Gauthier T, Faure-Virelizier C, Vaini-Cowen V, Lantheaume S, Regis C, Darai E, Ceccato V, D'Halluin G, Del Piano F, Villet R, Jouve E, Beedassy B, Theret P, Gabelle P, Zinzindohoue C, Opinel P, Marsollier-Ferrer C, Dhainaut-Speyer C, Colombo PE, Lambaudie E, Tallet A, Boher JM; Others investigators (SERC trial group). Houvenaeghel G, et al. Among authors: de lara ct. BMC Cancer. 2018 Nov 21;18(1):1153. doi: 10.1186/s12885-018-5053-7. BMC Cancer. 2018. PMID: 30463611 Free PMC article. Clinical Trial.
30 results